Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion
VX18-CTX001-131
Phase 3 small_molecule active
Quick answer
Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion for Sickle Cell Disease, Transfusion dependent thalassemia is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vertex Pharmaceuticals (Ireland) Limited
- Indication
- Sickle Cell Disease, Transfusion dependent thalassemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active